He was practicing as a Medical Oncologist at a full consultative level before joining the Huron Medical Clinic in Port Huron, Michigan as a private practitioner. He also served on many committees and acted as a consultant to hospitals in the area including Port Huron Hospital, Mercy Hospital, and River District Hospital.
As a valued Principal Investigator, Dr. Hanna’s research in primary breast cancer therapy was published in Volume 8, Number 3, of The Breast Journal. He has also served as Principal Investigator in several clinical studies.
PERSONAL INFORMATION:
Place of Birth: Damascus, Syria
Citizenship: United States of America
Marital Status: Married (3 daughters)
LICENSE AND BOARD CERTIFICATION:
American Board of Internal Medicine: Certified (1996 – 2015)
American Board of Internal Medicine, Medical Oncology: Certified (2000 – 2015)
Board Certified and Licensed by the State of Michigan
EDUCATION:
Degree: Doctor of Medicine Damascus University School of Medicine
Graduation: Class of 1992 {Ranking: Excellent}
Internship: Providence Hospital; Southfield, Michigan 1993 – 1994
Residency: Providence Hospital; Southfield, Michigan 1994 – 1996
Fellowship in Medical Oncology: Beaumont Hospital; Royal Oak, Michigan 1998-2000
Examination: American Board of Internal Medicine: August 1996, Score: Decile 10
CLINICAL EXPERIENCE:
Two years practicing as a Primary Care Physician 1996 – 1998. Currently a practicing Medical Oncologist at full consultant level since July 2000; full partner at work.
MEMBERSHIP:
American Medical Association, American Society of Clinical Oncology,
American Society of Hematology, Michigan State Medical Society,
Michigan Society of Hematology Oncology, Saint Clair County Medical Society,
Port Huron Hospital IRB Member.
RESEARCH:
August 2004- Principal Investigator; A phase three randomized controlled study comparing iron sucrose (venofer) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin therapy.
February 12, 2004- Principal Investigator; 20020122: A randomized, open label, multicenter study of primary versus secondary prophylaxis with Neulasta (pegfilgrastin) as an adjunct to chemotherapy in elderly subjects (> 65 years old) with cancer.
June 2003- Principal Investigator; A multicenter, retrospective survey of the incidence of anemia and outcomes of erythropoietin therapy in patients receiving systemic chemotherapy for cancer protocol P01-02-004-020.
March 2003- Sub investigator; Protocol H3e-us-jmfe open label study of Alimta (Pemetrexed) alone or in combination with Cisplatin for patients with malignant mesothelioma.
Excessive toxicity with concurrent adjuvant Radiation therapy and Paclitaxel in breast cancer patients'. Presented at the San Antonio breast cancer symposium. BUDR improves the cytoxic effect of Cisplatin; presented at OHEP center May 1995, and at the ACP meeting September 1995 (Third Award).
PUBLICATIONS:
Acute and sub acute toxicity associated with concurrent adjuvant radiation therapy and Paclitaxel in primary breast cancer therapy: The Breast Journal, Volume 8, Number 3, 2002 149-153 First Author.
HOSPITAL AFFILIATIONS:
McLaren Port Huron Hospital
1221 Pine Grove Avenue
P.O. Box 5011
Port Huron, MI 48061-5011
Phone: 810-987-5000
Staff Category: Active (OCT 1998-current)
Mercy Hospital/Port Huron
2601 Electric Avenue
Port Huron, MI 48060-6518
Phone: 810-985-1500
Staff Category: Active (JAN 1999-current)
River District Hospital
St John Health System
4100 River Road
East China, MI 48054-2914
Phone: 810-329-7111
Staff Category: Consultant (Jan. 1999-current)
LANGUAGES:
Arabic
French
English